본문 바로가기

Predictors of active surveillance discontinuation in prostate cancer: Large Korean multicenter cohort study

문서 유형
연구출판물 · 학술지 논문
등재
KCISCIEScopus
저널 순위
JCR Q2Scopus Q2KCI Q3
저널
Investigative and Clinical Urology67(5) · pp.459 · 2026
피인용
Web of Science 0Scopus 0KCI 0
FWCI (Scopus)
0
JCR IF
JCR 2024 2.1
ISSN
2466-0493

저자

  1. Choi, Joongwon제1저자Chung Ang Univ, Coll Med, Dept Urol, Gwangmyeong Hosp, Gwangmyeong, South Korea
  2. Lee, Chung UnChung Ang Univ, Coll Med, Dept Urol, Gwangmyeong Hosp, Gwangmyeong, South Korea
  3. Jeon, Seong SooSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
  4. Byun, Seok SooSeoul Natl Univ, Coll Med, Dept Urol, Bundang Hosp, Seongnam, South Korea
  5. Joung, Jae YoungNatl Canc Ctr, Ctr Urol Canc, Dept Urol, Goyang, South Korea
  6. Ahn, HanjongKangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Urol, Sch Med, Chunchon, South Korea
  7. Cho, Jin SeonHallym Univ, Sacred Heart Hosp, Coll Med, Dept Urol, Anyang, South Korea
  8. 박성우Pusan Natl Univ, Yangsan Hosp, Sch Med, Dept Urol, Yangsan, South Korea
  9. Kwon, Dong DeukChonnam Natl Univ, Med Sch, Dept Urol, Hwasun Hosp, Hwasun, South Korea
  10. Ha, U-SynCatholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Urol, Seoul, South Korea
  11. Park, Jae YoungKorea Univ, Ansan Hosp, Dept Urol, Coll Med, Ansan, South Korea
  12. Kwon, Tae GyunKyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Urol, Daegu, South Korea
  13. Jo, Jung KiHanyang Univ, Hanyang Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
  14. Jeong, Chang WookSeoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
  15. Kwak, Cheol교신저자Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea

초록

Purpose: Active surveillance (AS) is an established management strategy for favorable-risk prostate cancer (PCa). In real-world practice, decisions to continue AS or active treatment (AT) are influenced by both disease-related and patient-related factors. This study aimed to identify factors associated with the transition from AS to AT in a large multicenter cohort. Materials and Methods: We analyzed 716 patients with PCa managed with AS across 12 institutions. Baseline clinical characteristics, comorbidity burden assessed via the Charlson comorbidity index (CCI), performance status evaluated using the Eastern Cooperative Oncology Group (ECOG) score, and disease-related factors, including prostate-specific antigen (PSA), PSA density (PSAD), and magnetic resonance imaging findings, were collected. Cox proportional hazards regression was used to identify factors associated with conversion to AT. Results: During a mean follow-up of 28.4 months, 224 patients (31.3%) transitioned from AS to AT, most frequently because of pathologic reclassification (60.3%). In multivariate analysis, maximum core involvement (hazard ratio [HR] 1.015, p=0.003) and PSAD >= 0.10 ng/mL/cm3 (HR 1.478, p=0.044) were independently associated with conversion to AT. Although ECOG performance status and CCI were not statistically significant in multivariate models, patients with poorer functional status or greater comorbidConclusions: In this large multicenter study, PSAD was the strongest predictor of transition to AT during AS for PCa. Beyond disease-related factors, patient condition also appeared to influence real-world decisions about continuing AS.

키워드

Active surveillanceProstate cancerRisk factorsTreatment outcomePSA DENSITYRISKMEN

식별자

Scopus EID
2-s2.0-105048965794
WoS UID
001841828000001
KCI
ART003378668